Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06307613
Other study ID # ARGX-113-2301
Secondary ID 2023-509197-35-0
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 27, 2024
Est. completion date October 2027

Study information

Verified date June 2024
Source argenx
Contact Sabine Coppieters, MD
Phone 857-350-4834
Email clinicaltrials@argenx.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively during the double-blinded treatment period (DBTP). At the end of the DBTP, participants may enter a follow-up observational period while off study drug. Some participants may also enter the open-label treatment period with efgartigimod PH20 SC. The study duration varies from approximately 60 to 110 weeks. An alternative list of clinical sites open for recruitment could be found in the other UplighTED study record (https://www.clinicaltrials.gov/study/NCT06307626)


Recruitment information / eligibility

Status Recruiting
Enrollment 108
Est. completion date October 2027
Est. primary completion date February 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - The participant is at least 18 years of age - The participant is capable of providing signed informed consent and following with protocol requirements - The participant has a physician's diagnosis of active, moderate-to-severe thyroid eye disease (TED) associated with autoimmune thyroid conditions (Graves' disease or Hashimoto's thyroiditis) for the most severely affected eye - The participant has onset of active TED symptoms within 12 months before screening - The participant must have normal thyroid function with the baseline disease under control or have mild hypo or hyperthyroidism at screening. Every effort should be made to correct the mild hypo or hyperthyroidism promptly and to maintain the normal thyroid function for the full duration of the study - The participant agrees to use birth control consistent with local regulations and the people of child-bearing potential must have a negative blood pregnancy test at screening and a negative urine pregnancy test before receiving the study drug Exclusion Criteria: - Optic neuropathy (damage to optic nerve), defined as new visual field defect (blind spot), relative afferent pupillary defect (pupils respond differently to light), or color defect secondary to optic nerve involvement within the 6 months before screening - Corneal decompensation (swelling of the cornea) unresponsive to medical management - Previous orbital irradiation or surgery for TED - Use of some medications before screening (more information is found in the protocol) - Known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of TED or puts the participant at undue risk - History of malignancy, cancer, unless considered cured by adequate treatment with no evidence of recurrence for =3 years. Adequately treated participants with the following cancers can be included at any time: Basal cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histological findings of prostate cancer - Clinically significant active infection that is not sufficiently resolved in the investigator's opinion or positive serum test at screening for active infection with any of the following: Hepatitis B virus (HBV), Hepatitis C virus (HCV), HIV - Current participation in another interventional clinical study or previous participation in an efgartigimod clinical study and at least 1 dose of study drug received or has received at least 1 dose of commercially available efgartigimod - Known hypersensitivity to study drug or one of its excipients (inactive ingredients) - History of or current alcohol, drug, or medication abuse within 12 months before screening as assessed by the investigator - Pregnant or lactating state or intention to become pregnant during the study - Live or live-attenuated vaccine received <4 weeks before screening The complete list of exclusion criteria can be found in the protocol.

Study Design


Intervention

Combination Product:
Efgartigimod PH20 SC
Subcutaneous efgartigimod PH20 SC given by prefilled syringe
Other:
Placebo PH20 SC
Subcutaneous placebo given by prefilled syringe

Locations

Country Name City State
United States Advanced Clinical Research Coral Springs Florida
United States Moyes Eye Center Kansas City Missouri

Sponsors (1)

Lead Sponsor Collaborator
argenx

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of participants who were proptosis responders At week 24 of the Double-Blinded Treatment Period
Secondary Change in proptosis measurement in the study eye from baseline Up to week 24 of the Double-Blinded Treatment Period
Secondary Change in the total Graves' Orbitopathy Quality of Life (GO-QoL) score from baseline Minimum value: 0 (most negative impact on Quality of Life); Maximum value: 100 (No impact on Quality of Life) Up to week 24 of the Double-Blinded Treatment Period
Secondary Percentage of participants with a resolution of diplopia (responders) At week 24 of the Double-Blinded Treatment Period
See also
  Status Clinical Trial Phase
Completed NCT04583735 - A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease Phase 4
Active, not recruiting NCT05002998 - TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study Phase 4
Withdrawn NCT02422368 - The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Phase 2/Phase 3
Completed NCT03298867 - Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study Phase 3
Recruiting NCT05987423 - A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease Phase 3
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Recruiting NCT05517447 - Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease Phase 3
Terminated NCT04737330 - A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) Phase 3
Recruiting NCT05517421 - Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Phase 3
Recruiting NCT04311606 - Anti-VEGF Therapy for Acute Thyroid Eye Disease Phase 2
Recruiting NCT06106828 - A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease (SatraGO-2) Phase 3
Recruiting NCT06021054 - A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED) Phase 3
Not yet recruiting NCT06413043 - Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy N/A
Not yet recruiting NCT06401044 - A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease Phase 1
Recruiting NCT06384547 - A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) Phase 3
Recruiting NCT06367517 - Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)
Recruiting NCT06275373 - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Enrolling by invitation NCT05241626 - AS-OCT of the Cornea in Thyroid Diseases
Active, not recruiting NCT05776121 - Study of ZB001 in Chinese Patients With Thyroid Eye Disease Phase 1
Recruiting NCT04359979 - Tamsulosin for Thyroid Lid Retraction N/A